Last updated: February 25, 2026
What Is the Drug and Its Approved Indication?
NDC 00713-0353 corresponds to Ritlecitinib (CLGN-1067), developed by Pfizer. It is an oral Janus kinase (JAK) inhibitor targeting autoimmune conditions, primarily alopecia areata. Approved by the U.S. Food and Drug Administration (FDA) in October 2022, it is marketed as Litfulo.
Market Size and Demand Drivers
Indication and Patient Population
| Parameter |
Details |
| Approved Use |
Alopecia areata (FDA approval in Oct. 2022) |
| Estimated Patients |
Approximately 300,000 in the U.S. with severe or patchy alopecia areata |
| Demographics |
Affects men and women, with higher prevalence in young adults and adolescents |
Market Growth Factors
- Incidence: Estimated at 0.2% of the population globally, with prevalence rising due to better diagnosis.
- Unmet Need: Few approved treatments; existing options include corticosteroids and immunotherapies, with variable efficacy.
- Market Entry Impact: First oral JAK inhibitor approved specifically for alopecia areata enhances market penetration potential.
- Expansion Potential: Possible future indications include vitiligo and other autoimmune dermatological diseases.
Competitive Landscape
| Competitor |
Key Products |
Market Status |
Notes |
| Brand-name JAK inhibitors |
Olumiant (baricitinib), Xeljanz (tofacitinib) |
Off-label, limited FDA approval |
Used off-label for alopecia areata with variable success |
| Other dermatological drugs |
corticosteroids, anthralin |
First-line, symptomatic |
Limited efficacy, high relapse rates |
| Emerging treatments |
Baricitinib (Eli Lilly), Deuruxolitinib (Incyte) |
Clinical trials ongoing |
Potential future competitors |
Pricing Trends
List Price and Reimbursement
| Parameter |
Details |
| FDA-approved Price (list price, 30-day supply) |
Approximately $3,200 to $3,600 per month |
| Medicaid/Commercial Pricing Adjustment |
Usually 10-20% discounts via Negotiation |
| Average Wholesale Price (AWP) |
Around $3,000 to $3,500 per month |
Price Comparison with Similar Drugs
| Drug |
Indication |
Monthly Price (Approximate) |
Notes |
| Olumiant (baricitinib) |
Rheumatoid arthritis |
$3,100 - $3,300 |
Used off-label for alopecia areata |
| Xeljanz (tofacitinib) |
Rheumatoid arthritis |
$2,900 - $3,200 |
Similar JAK inhibitor, different indication |
Pricing Outlook
- Initial Launch Price: Around $3,200 per month aligns with other oral JAK inhibitors.
- Price Adjustments: Expect discounts in managed care negotiations, potentially reducing net prices by 15-25%.
- Market Trends: Pricing consistency expected as the drug gains market share in a niche segment.
Revenue Projections
| Year |
Estimated U.S. Annual Revenue |
Assumptions |
| 2023 |
$100 million |
Initial uptake, capturing 15% of target population |
| 2024 |
$250 million |
Growing prescriber base, increased insurance coverage |
| 2025 |
$400 million |
Expanded indications and comprehensive payer inclusion |
Factors Influencing Revenue
- Market penetration speed: Influenced by physician awareness and insurance reimbursement.
- Pricing strategy: Slight discounting for wider access and formulary inclusion.
- Patent and exclusivity: Patent expires in 2037, potentially affecting long-term pricing.
Regulatory and Reimbursement Environment
- FDA approval: Clear indication for alopecia areata streamlines reimbursement processes.
- Pricing policies: Managed care organizations may negotiate rebates to include the drug on formularies.
- International prospects: Licensing deals are ongoing in key markets like Europe and Japan, which could influence global revenue.
Risks and Opportunities
| Risks |
Opportunities |
| Off-label competition from existing JAK inhibitors |
First FDA-approved treatment specifically for alopecia areata |
| Potential side effects influencing marketability |
Expansion into other autoimmune dermatology indications |
| Pricing pressures from payers |
Orphan drug designation could influence pricing strategies |
Key Takeaways
- NDC 00713-0353 (Litfulo) launched at approximately $3,200/month, positioning it competitively among JAK inhibitors.
- The target market in the U.S. comprises roughly 300,000 patients with alopecia areata, with revenues projected to reach up to $400 million annually by 2025.
- Market entry benefits from being the first oral JAK inhibitor approved explicitly for alopecia areata; competition currently exists off-label.
- Price negotiation strategies and payer inclusion will significantly influence net revenues.
- Expansion to other indications and markets could further increase market share and revenue streams.
FAQs
Q1: What is the primary indication for NDC 00713-0353?
A: It is approved for treating alopecia areata in adults and adolescents.
Q2: How does the drug’s pricing compare with other JAK inhibitors?
A: The list price is similar to Olumiant and Xeljanz, ranging from $3,000 to $3,600 monthly.
Q3: What is the long-term revenue potential?
A: By 2025, revenues could reach $400 million annually in the U.S., assuming steady market adoption and reimbursement.
Q4: Are there any significant regulatory hurdles for future indications?
A: No, the FDA approval is specific for alopecia areata; additional indications will require new approvals and clinical trials.
Q5: How might payers influence the drug’s market penetration?
A: Rebate negotiations and formulary positioning will impact access and, consequently, sales volumes.
References
[1] FDA. (2022). FDA approves first oral Janus kinase inhibitor for alopecia areata. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-janus-kinase-inhibitor-alopecia-areata
